A5032196793- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Endometriosis Research and Treatment
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- RNA Interference and Gene Delivery
- Vascular Tumors and Angiosarcomas
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Beetle Biology and Toxicology Studies
- Renal cell carcinoma treatment
- Ocular Oncology and Treatments
- Cancer-related cognitive impairment studies
- PARP inhibition in cancer therapy
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- Cardiac tumors and thrombi
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2016-2025
Kettering University
2006-2022
The University of Texas Southwestern Medical Center
2019
National Health Service
2018
Radboud University Medical Center
2018
University of Birmingham
2018
Radboud University Nijmegen
2018
Centre Léon Bérard
2017
Dana-Farber Cancer Institute
2009-2017
In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts the blood all this trial who had complete cytogenetic remission.Levels by quantitative real-time polymerase-chain-reaction assay. Results expressed relative median level 30 untreated CML phase.In remission, after 12 months treatment fallen at least 3 log 57 percent those group and 24 given...
Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA mutations who have completed childbearing. However, there are limited data supporting the efficacy this approach. We prospectively compared effect risk-reducing with that surveillance for ovarian cancer on incidence subsequent breast and BRCA-related gynecologic cancers in women mutations.
This multicenter study, to our knowledge, is the first phase III trial compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy an anthracycline and at least one additional systemic regimen.Patients were randomly assigned a 2:1 ratio receive intravenously every 3 weeks. The primary end point was overall survival (OS), secondary points disease control-progression-free (PFS), time progression, objective response rate, duration of...
Purpose Gemcitabine as a single agent and the combination of gemcitabine docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if addition to improved clinical outcome sarcomas, we compared fixed dose rate infusion versus lower docetaxel. Patients Methods In this open-label phase II trial, primary end point was tumor response, defined complete or partial response stable disease lasting at least 24 weeks. A Bayesian adaptive randomization procedure used produce...
PURPOSE: Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response gemcitabine plus docetaxel among patients with LMS. PATIENTS AND METHODS: Patients unresectable of uterine (n = 29) or other 5) primary sites who did not respond zero two prior regimens were enrolled onto a phase II study 900 mg/m 2 intravenously (IV) on days 1 and 8 100 IV day granulocyte colony-stimulating factor given...
PURPOSE Since activity of sorafenib was observed in sarcoma patients a phase I study, we performed multicenter II study daily oral with recurrent or metastatic sarcoma. PATIENTS AND METHODS We employed multiarm design, each representing subtype its own Simon optimal two-stage design. In arm, 12 who received 0 to 1 prior lines therapy were treated (0 3 for angiosarcoma and malignant peripheral-nerve sheath tumor). If at least one Response Evaluation Criteria Solid Tumors (RECIST) observed, 25...
To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer.An committee reviewed literature published since last in 2002.Thirty-nine reports met inclusion criteria: palifermin dexrazoxane, three (two studies) each; amifostine, 33 (31 studies); mesna, no randomized trials identified 2002.Dexrazoxane is not recommended routine breast cancer (BC) adjuvant setting, or metastatic setting initial doxorubicin-based chemotherapy....
Long peptides are efficiently presented to both CD4(+) and CD8(+) T cells after intracellular processing by antigen-presenting cells. To investigate the safety in vivo immunogenicity of synthetic overlapping long (OLP) from a human tumor self-antigen, we conducted phase I clinical trial with OLP cancer-testis antigen NY-ESO-1 various adjuvant combinations.Twenty-eight patients advanced ovarian cancer second or third remission were enrolled sequentially three cohorts received at least one...
To describe the incidence of low-volume ultrastage-detected metastases in sentinel lymph nodes (SLNs) identified at surgical staging for endometrial carcinoma and to correlate it with depth myoinvasion tumor grade.We reviewed all patients who underwent primary surgery successful mapping least one SLN our institution from September 2005 December 2011. All a cervical injection mapping. The ultrastaging protocol involved cutting an additional 2 adjacent 5-μm sections each levels, 50-μm apart,...
Abstract The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification therapeutic targets, research, advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or few subtypes. Herein, we report comparative analysis 2,138 representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable...
This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to ifosfamide (PI) for treating uterine carcinosarcoma (UCS).Adults with chemotherapy-naïve UCS or ovarian (OCS) were randomly assigned PC PI 3-week cycles 6-10 cycles. With 264 events in patients UCS, power an overall survival (OS) hybrid noninferiority design was 80% a hazard ratio (HR) of 1.2 against 13% greater death rate on type I error 5% one-tailed test.The study...
PURPOSE:Because toxicities associated with chemotherapy and radiotherapy canadversely affect short- long-term patient quality of life, can limitthe dose duration treatment, may be life-threatening, specificagents designed to ameliorate or eliminate certain andradiotherapy have been developed. Variability in interpretationof the available data pertaining efficacy three United StatesFood Drug Administration–approved agents that potentialchemotherapy- radiotherapy-protectant...
Purpose Tracking symptoms related to treatment toxicity is standard practice in routine care and during clinical trials. Currently, clinicians collect symptom information via complex often inefficient mechanisms, but there growing interest collecting outcome directly from patients. Patients Methods The National Cancer Institute Common Terminology Criteria for Adverse Events schema seven common was adapted into a Web-based patient-reporting system, accessible desktop computers outpatient...
Article Tools ASCO SPECIAL ARTICLE OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles CITATION DOI: 10.1200/JCO.2002.04.178 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12065567 2002 Update Recommendations for the Use Chemotherapy and Radiotherapy Protectants: Practice Guidelines American Society Lynn M. SchuchterxLynn SchuchterSearch by this author , Martee L. HensleyxMartee...
To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies cancer incidence in a cohort individuals at hereditary risk for breast ovarian cancer.Two hundred fifty-one with BRCA mutations were identified single comprehensive center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening preventive surgery provided context counseling. Patients followed mean 24.8 months (range, 1.6 to 66.0 months) using standardized...
Purpose: Quality of life (QOL) outcomes in patients with chronic myeloid leukemia (CML) were evaluated an international phase III study. Patients and Methods: Newly diagnosed CML randomly assigned to imatinib or interferon alfa plus subcutaneous low-dose cytarabine (IFN+LDAC). Cross-over the other treatment was permitted because intolerance lack efficacy. completed cancer-specific QOL (Functional Assessment Cancer Therapy–Biologic Response Modifiers) utility (Euro QoL-5D) questionnaires at...
Patients who have undergone supracervical hysterectomy or uterine morcellation for presumed benign disease and are found to malignancy on final pathology represent a management dilemma. Our goal was analyze our experience make observations regarding staging, treatment, outcomes. We performed retrospective case series of patients referred institution with previously underwent at the time original surgery disease. Between January 2000 March 2006, 17 were identified. Following initial surgery,...